title: ISA247: quality of life results from a phase II, randomized, placebo-controlled study.
abstract: BACKGROUND
  Psoriasis is a chronic skin condition that can negatively affect a patient's quality of life (QoL), often hindering social functioning. ISA247, a novel psoriatic agent, has shown clinical efficacy in moderate to severe psoriasis sufferers, but its effect on QoL is currently not reported.
  
  
  OBJECTIVE
  The objective of this study was to assess the effect of ISA247 on the QoL in patients with stable, plaque-type psoriasis.
  
  
  METHODS
  A phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study assessed the effects of ISA247 doses of 0.5 mg/kg/d (n = 77) or 1.5 mg/kg/d (n = 83) compared with placebo (n = 41) for 12 weeks. QoL was assessed using the Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index (PDI) scales.
  
  
  RESULTS
  ISA247 treatment (pooled groups) significantly improved QoL scores as assessed by both the DLQI and the PDI compared with those receiving placebo (p < .05). Treatment with the higher dose of 1.5 mg/kg/d demonstrated a significantly greater response to many of the QoL scales compared with the 0.5 mg/kg/d group (p < .05).
  
  
  CONCLUSIONS
  ISA247 appears to improve the QoL while also providing effective treatment for chronic, moderate to severe, plaque-type psoriasis.
authors.affiliation: Sunnybrook and Women's College Health Sciences Centre, Toronto, ON. agupta@aculink.com
authors.forename: Aditya K
authors.initials: AK
authors.lastname: Gupta
authors.forename: Richard G
authors.initials: RG
authors.lastname: Langley
authors.forename: Charles
authors.initials: C
authors.lastname: Lynde
authors.forename: Kirk
authors.initials: K
authors.lastname: Barber
authors.forename: Wayne
authors.initials: W
authors.lastname: Gulliver
authors.forename: Gilles
authors.initials: G
authors.lastname: Lauzon
authors.forename: Launa J
authors.initials: LJ
authors.lastname: Aspeslet
authors.forename: Robert T
authors.initials: RT
authors.lastname: Foster
authors.forename: Robert B
authors.initials: RB
authors.lastname: Huizinga
authors.forename: Randall W
authors.initials: RW
authors.lastname: Yatscoff